Portal de Periódicos da CAPES

The use of proprietary medicines by patients presenting with peptic ulcer haemorrhage.

1993; Wiley; Volume: 35; Issue: 5 Linguagem: Inglês

10.1111/j.1365-2125.1993.tb04168.x

1365-2125

J B Marriott, PA Asquith, CJ Shorrock,

Autoimmune Bullous Skin Diseases

1. Medication, social and symptom histories were compared in patients with severe haemorrhage from a peptic ulcer (n = 71) and matched control subjects. Self‐medication with proprietary agents was catalogued in addition to therapy prescribed by general medical practitioners. 2. Prior to the bleed, only 4% of ulcer patients had been free of symptoms normally associated with peptic ulceration, whereas 76% of the control group had been asymptomatic. 3. Gastro‐ irritant proprietary medicines were used regularly by 23% of ulcer patients compared with only 4% of controls. However, proprietary antacids were used chronically by 46% of ulcer patients compared with only 7% of controls. Bicarbonate was the antacid of choice used by 13% of ulcer patients. The odds ratio for the association between development of bleeding peptic ulcer and the use of indigestion remedies was 11.5% (95% CI 1.1, 121). 4. Fifty‐one percent of ulcer patients were prescribed agents known to cause gastro‐intestinal damage, whereas only 25% of the control group were prescribed similar agents. Only 7% of the control group were prescribed anti‐ulcer therapy compared with 37% of those with bleeding ulcer. 5. A large proportion of patients with haemorrhage from a peptic ulcer had had symptoms sufficient to warrant recourse to self‐medication with antacids without medical knowledge. Exacerbation of peptic ulcer by self‐medication with proprietary products is likely to be of lesser significance.